SCHEMBL22729834

SCHEMBL22729834

COc1cccc(C23CCN(C(=O)c4cn(C)c5c(C)cn(C)c(=O)c45)CC2C3)c1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.39
▸ MGLL Q99685 2/20 0.39
▸ PROKR1 Q8TCW9 2/20 0.38
▸ GRIN2B Q13224 4/20 0.38
▸ SLC6A4 P31645 2/20 0.37
▸ SIGMAR1 Q99720 3/20 0.37
▸ KDM4E B2RXH2 2/20 0.37
▸ ALOX15 P16050 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ OPRD1 P41143 2/20 0.37
▸ SLC6A2 P23975 1/20 0.37
▸ SLC6A3 Q01959 1/20 0.37
▸ HCRTR1 O43613 1/20 0.35
▸ HCRTR2 O43614 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22729791 0.91 GRIN2B (0.39) ALDH1A1MGLLPROKR1GRIN2BSLC6A4
SCHEMBL29839306 0.91 MGLL (0.41) ALDH1A1MGLLKDM4EALOX15MAPK1
SCHEMBL22729459 0.91 MGLL (0.41) ALDH1A1MGLLKDM4EALOX15MAPK1
SCHEMBL22729795 0.89 MGLL (0.41) ALDH1A1MGLLPROKR1KDM4EALOX15
SCHEMBL22729763 0.89 ALDH1A1 (0.40) ALDH1A1MGLLKDM4EALOX15MAPK1
SCHEMBL23139780 0.85 KDM4E (0.41) ALDH1A1SIGMAR1KDM4EALOX15MAPK1
SCHEMBL22729433 0.85 ALDH1A1 (0.38) ALDH1A1MGLLPROKR1GRIN2BSIGMAR1
SCHEMBL29839308 0.85 ALDH1A1 (0.38) ALDH1A1MGLLPROKR1GRIN2BSIGMAR1
SCHEMBL22729740 0.84 MGLL (0.41) ALDH1A1MGLLKDM4EALOX15MAPK1
SCHEMBL29839319 0.84 MGLL (0.41) ALDH1A1MGLLKDM4EALOX15MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11459325-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-10-04 — — US disclosed
US-20210087186-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-03-25 — — US disclosed
US-20210087186-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-03-25 — — US disclosed
EP-3747885-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2020-12-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210087186-A1 HETEROCYCLIC COMPOUND GBA1, GBA2, GALC ALDH1A1 2626/4885MGLL 92/4885PROKR1 3517/4885
US-11459325-B2 Heterocyclic compound GBA1, GBA2, GALC ALDH1A1 2660/4885MGLL 91/4885PROKR1 3556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback